Form 4: Astria Therapeutics Director Kenneth Bate Granted Stock Options Valued at $5.79 Per Share

Astria Therapeutics, Inc. Director Kenneth Bate was granted 26,550 stock options with an exercise price of $5.79 per share, aligning his interests with shareholder value.

Summary

• Kenneth Bate, a Director at Astria Therapeutics, Inc. (ATXS), was granted 26,550 stock options.
• The options have an exercise price of $5.79 per share.
• The grant date for these options was June 11, 2025.
• The options will vest in their entirety on the one-year anniversary of the grant date, specifically June 11, 2026, contingent on the director's continued service.
• The expiration date for these stock options is June 10, 2035.
• Following this transaction, Kenneth Bate beneficially owns 26,550 derivative securities directly.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While a Form 4 itself doesn't convey financial performance, the grant of options to a director is a positive signal of continued alignment between the board and shareholder interests. It's a routine compensation event, so not highly impactful on its own, but generally viewed favorably as it incentivizes long-term value creation.

Positives

• The grant of stock options to a director aligns management's and the board's interests with those of shareholders, as the options gain value only if the stock price increases.
• This is a standard form of compensation for directors, indicating ongoing commitment and incentivization.

Future Outlook

The granted stock options are set to vest on June 11, 2026, contingent on the director's continued service, providing a future incentive for performance.

Management Comments

• The filing was signed by Ben Harshbarger, as attorney-in-fact for Kenneth Bate.

Industry Context

The granting of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, including companies like Astria Therapeutics, to attract and retain talent, and to align the interests of the board with long-term shareholder value creation. This type of compensation is prevalent across publicly traded companies as a means of incentivizing performance and fostering a sense of ownership among key personnel.

Comparison to Industry Standards

• Granting stock options as part of director compensation is a standard practice across various industries, including biotech, aligning with corporate governance best practices to incentivize long-term performance.
• The vesting schedule of one year is common for director equity grants, ensuring continued commitment.
• The exercise price being at or above the market price on the grant date (implied by the $0 price of the derivative itself and the $5.79 exercise price) is typical for incentive stock options.

Related Party Transactions

• The transaction involves a stock option grant from Astria Therapeutics, Inc. to Kenneth Bate, a Director of the company, which is considered a related party transaction as it involves an insider.

Stakeholder Impact

• Shareholders: The option grant aligns the director's financial interests with those of shareholders, as the options' value increases with the company's stock price, potentially encouraging decisions that enhance shareholder value.
• Employees: While not directly impacting employees, a well-compensated and incentivized board can lead to better strategic direction, which indirectly benefits all employees.

Next Steps

• The stock options granted to Kenneth Bate are scheduled to vest on June 11, 2026, subject to his continued service as a director.

Key Dates

Keywords

Astria Therapeutics, ATXS, Stock Options, Director Compensation, SEC Form 4, Insider Transaction, Equity Grant, Beneficial Ownership